A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.
Anuja ChatterjeeGijs van de WeteringRon GoereeCarolyn OwenAnne Marie DesboisStephane BarakatBeenish S ManzoorKavita SailPublished in: PharmacoEconomics - open (2022)
VEN+O is a cost-effective treatment option for unfit frontline CLL patients and provides value for money to healthcare payers.